Gentiopicroside alleviates pain-depression comorbidity in reserpine-induced models by downregulating glutamate NMDA receptor subunit 2B (GluN2B) subunit expression of NMDA receptors in the basolateral amygdala, reducing glutamatergic excitotoxicity. This evidence concerns the gene GRIN2B and depressive symptom measurement.